Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2330-2339

  Cao, Deliang ^a   Ziemba, Amy ^c   McCabe, James ^b   Yan, Ruilan ^a   Wan, Laxiang ^b   Kim, Bradford ^b   Gach, Michael ^c   Flynn, Stuart ^b   Pizzorno, Giuseppe ^b,c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; URIDINE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; FLUORINE NUCLEAR MAGNETIC RESONANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PRODRUGS; PYRIMIDINES; TREATMENT OUTCOME; URIDINE PHOSPHORYLASE;

EID: 83355166905     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0202     Document Type: Article

References (50)

1. Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe S, Miyashita H, et al. Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 2002;97:631-5. (Pubitemid 34087802)
2. Liu M, Cao D, Russell R, Handschumacher RE, Pizzorno G. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 1998;58:5418-24. (Pubitemid 28551125)
3. Zhang D, Cao D, Russell R, Pizzorno G. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res 2001;61:6899-905. (Pubitemid 32896516)
4. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992;182:1232-9.
5. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, et al. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 1993;84:341-7.
6. Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G. Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 2005;280:21169-75. (Pubitemid 40805678)
7. Cao D, Pizzorno G. Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 2004;40:431-43. (Pubitemid 38858910)
8. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
9. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002;62:2313-7. (Pubitemid 34411710)
10. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 2002;1587:133-44. (Pubitemid 34655783)
11. Wan L, Cao D, Zeng J, Yan R, Pizzorno G. Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the Capecitabine intermediate 50-deoxy-5- fluorouridine in breast cancer cells. Mol Pharmacol 2006;69:1389-95.
12. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5- fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986;46:20-8. (Pubitemid 16189022)
13. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92. (Pubitemid 37386604)
14. de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003;88:957-64. (Pubitemid 36520887)
15. Evrard A, Ciccolini J, Cuq P, Cano JP. Enzyme-prodrug systems: thymidine phosphorylase/5′-deoxy-5-fluorouridine. MethodsMolMed 2004;90:263-78.
16. Tabata T, Katoh M, TokudomeS, Nakajima M, Yokoi T. Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from Capecitabine in human liver. Drug Metab Dispos 2004;32:1103-10. (Pubitemid 39287584)
17. Hiehle JF Jr, Levine MS. Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. Can Assoc Radiol J 1991;42:109-12.
18. Ohta Y, Tezuka E, Tamura S, Yagi Y. Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity. Int J Immunopharmacol 1985;7:761-8. (Pubitemid 16255842)
19. Pizzorno G, Davis SJ, Hartigan DJ, Russello O. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)-5,10-dideazatetrahydrofolic acid. Biochem Pharmacol 1994;47:1981-8. (Pubitemid 24192052)
20. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991;19:4293.
21. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992;52: 4922-8.
22. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 2001;267:17102-9.
23. 19F nuclear magnetic resonance spectroscopy. Cancer Res 1999;59: 122-7.
24. Weiterova L, Hofer M, Pospisil M, Znojil V, Vacha J, Vacek A, et al. Influence of the joint treatment with granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on erythropoietic recovery following 5-fluorouracil-induced haematotoxicity in mice. Eur J Haematol 2000;65:310-6.
25. Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of theDPYDgene. Br J Cancer 2002;86:1028-33. (Pubitemid 34438069)
26. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37. (Pubitemid 19114713)
27. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-43. (Pubitemid 41131715)
28. Akazawa S, Kumai R, Yoshida K, Ayusawa D, Shimizu K, Seno T. The cytotoxicity of 5-fluorouracil is due to its incorporation into RNA not its inhibition of thymidylate synthase as evidenced by the use of a mouse cell mutant deficient in thymidylate synthase. Jpn J Cancer Res 1986;77:620-4. (Pubitemid 16072377)
29. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW. High-dose 5-fluorouracil with delayed uridine "Rescue" in mice. Cancer Res 1982;42:3964-70. (Pubitemid 13198549)
30. Van Laar JAM, Van der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM, et al. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-b carcinoma tumor model. Clin Cancer Res 1996;2:1327-33. (Pubitemid 26299431)
31. Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess 2004;8:iii, xiii-xvi, 1-143.
32. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001;61:2309-26. (Pubitemid 34074809)
33. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104. (Pubitemid 32242792)
34. Nishina T, Hyodo I, Miyaike J, Inaba T, Suzuki S, Shiratori Y. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 50-deoxy-5-fluorouridine. Eur J Cancer 2004;40:1566-71. (Pubitemid 38757745)
35. Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003;63:4268-74. (Pubitemid 36917956)
36. Kong X, Fan H, Liu X, Wang R, Liang J, Gupta N, et al. Peroxisome proliferator-activated receptor coactivator-1 enhances antiproliferative activity of 50-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase. Mol Pharmacol 2009;76:854-60.
37. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;334:1-8. (Pubitemid 28420963)
38. Focher F, Spadari S. Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 2001;1:141-53. (Pubitemid 33772392)
39. Martin DS, Stolfi RL, Sawyer RC. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 1989;24:9-14. (Pubitemid 19139983)
40. Darnowski JW, Handschumacher RE. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res 1985;45:5364-8.
41. Darnowski JW, Handschumacher RE. Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 1986;46:3490-4. (Pubitemid 16096897)
42. Chu SY, Weng ZY, Chen ZH, Rowe EC, Chu E, Naguib FNM, et al. Synthesis of 5-benzyl and 5-benzyloxybenzyl 2,2′-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase. Nucleos Nucleot 1988;7:91-102. (Pubitemid 18058200)
43. Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, et al. Clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 1998;4:1165-75. (Pubitemid 28213327)
44. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-20-deoxyuridine. Cancer Res 1979;39:2406-13. (Pubitemid 9203429)
45. Geoffroy FJ, Allegra CJ, Sinha B, Grem JL. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncology Res 1994;6:581-91.
46. Pritchard MD, Watson AJM, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A 1997;94:1795-99. (Pubitemid 27113915)
47. Schwartz GK, Christman K, Satlz L, Casper E, Ouan V, Bertino J, et al.A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue. Cancer 1996;78:1988-95. (Pubitemid 26360584)
48. Pastor-Anglada M, Casado FJ. Nucleoside transport into cells: role of nucleoside transporters SLC28 and SLC29 in cancer chemotherapy. In: Deoxynucleoside Analogs in Cancer Therapy, ed. Peters G. J. Totowa, NJ: Humana Press Publisher, 2006.
49. Farré X, Guillén-Gómez E,Sánchez L, Hardisson D, Plaza Y, Lloberas J, et al. Expression of the nucleoside derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004;112: 959-66. (Pubitemid 39507001)
50. Gloeckner-Hofmann K, Guillén-Gómez E,Schmidtgen C, Porstmann R, Ziegler R, Stoss O, et al. Expressionof the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 2006;70:238-44. (Pubitemid 44154698)